Medicine – Long-Term Oxygen Therapy

Long-term oxygen therapy (LTOT) is the regular administration of supplemental oxygen at home for patients with chronic severe resting hypoxaemia. It is used mainly in chronic respiratory diseases such as advanced COPD when persistent hypoxaemia remains despite optimal treatment of the underlying condition.

The major purpose of LTOT is not simply to relieve breathlessness. In appropriately selected patients with severe chronic hypoxaemia, prolonged oxygen therapy can improve survival and reduce some of the consequences of chronic tissue hypoxia.

⸻

1. Survival Benefit

Classic clinical trials demonstrated a significant survival benefit from long-term oxygen in patients with severe chronic hypoxaemia, particularly when oxygen was used for prolonged periods each day.

Older teaching sometimes describes approximately a 50% improvement in three-year survival in appropriately selected patients. The important clinical principle is that LTOT has a proven mortality benefit in patients with severe chronic resting hypoxaemia.

⸻

2. Duration of Oxygen Therapy

For LTOT to provide its established benefit, oxygen should generally be administered for at least 15 hours per day.

Greater daily use may provide additional benefit, and many patients are therefore encouraged to use oxygen for as much of the day and night as clinically appropriate.

⸻

3. Target Oxygenation

The oxygen flow rate is individually adjusted to correct significant hypoxaemia.

Traditional teaching aims to increase the arterial oxygen tension (PaO₂) above approximately 8 kPa (60 mmHg) while maintaining safe carbon dioxide levels.

The patient’s oxygen requirement should therefore be determined by formal assessment rather than simply prescribing an arbitrary oxygen flow rate.

⸻

Assessment for LTOT

4. Patient Must Be Clinically Stable

LTOT should not normally be permanently prescribed solely on measurements obtained during an acute respiratory exacerbation, because hypoxaemia may improve after recovery.

Assessment is therefore performed when the patient’s underlying disease has been optimally treated and clinically stable.

Older protocols commonly required arterial blood gases on two occasions several weeks apart. Current protocols vary by healthcare system, but the principle remains that chronic hypoxaemia should be confirmed in a stable patient.

⸻

5. Severe Resting Hypoxaemia

A classic indication for LTOT is a resting:

PaO₂ ≤7.3 kPa (55 mmHg)

when measured in a clinically stable patient.

This degree of persistent hypoxaemia is associated with adverse physiological consequences and is the group in which the survival benefit of LTOT is best established.

⸻

6. PaO₂ Between 7.3 and 8.0 kPa

LTOT may also be indicated when the resting PaO₂ is approximately 7.3–8.0 kPa (55–60 mmHg) if there is evidence of complications resulting from chronic hypoxaemia.

Important examples include pulmonary hypertension, peripheral oedema suggesting cor pulmonale, or secondary polycythaemia.

Therefore, a patient does not necessarily need a PaO₂ below 7.3 kPa if there is evidence that chronic hypoxaemia is already producing significant physiological consequences.

⸻

Cor Pulmonale

7. Chronic Hypoxaemia and the Right Heart

Persistent alveolar hypoxia causes pulmonary vasoconstriction.

When this occurs chronically, pulmonary vascular resistance increases and may eventually produce pulmonary hypertension.

The right ventricle must then pump against increased resistance, potentially resulting in right-sided cardiac dysfunction or cor pulmonale.

Correcting chronic hypoxaemia with LTOT can reduce hypoxic pulmonary vasoconstriction and help limit these consequences.

⸻

Carbon Dioxide

8. PaCO₂ May Be Normal or Raised

A raised arterial carbon dioxide tension (PaCO₂) does not automatically exclude a patient from receiving LTOT.

Some patients with advanced COPD have chronic hypercapnic respiratory failure and may still obtain substantial benefit from oxygen when they meet the appropriate hypoxaemia criteria.

⸻

9. Checking the Response to Oxygen

The patient’s response to supplemental oxygen should be assessed to ensure that oxygenation improves appropriately and that treatment does not cause clinically important worsening of hypercapnia or respiratory acidosis.

The older criterion that PaO₂ must rise above 8 kPa without a significant increase in PaCO₂ reflects this concern.

However, chronic hypercapnia itself is not an absolute contraindication to LTOT.

⸻

FEV₁ and LTOT

10. FEV₁ Below 1.5 L

Older criteria sometimes included an FEV₁ below 1.5 L as a requirement for LTOT.

This is now considered outdated as a strict eligibility criterion.

The decision to prescribe LTOT is primarily based on persistent chronic hypoxaemia and its complications, rather than a specific absolute FEV₁ value.

A patient can therefore meet criteria for LTOT without having an FEV₁ below 1.5 L.

⸻

Smoking and Oxygen Therapy

11. Smoking

Older protocols often stated that patients had to be non-smokers before LTOT could be prescribed.

Smoking cessation remains extremely important because continued smoking accelerates COPD progression and substantially reduces the overall benefit of respiratory treatment.

There is also a major fire and burn risk when smoking or using an open flame near supplemental oxygen.

However, whether active smoking represents an absolute contraindication to providing home oxygen varies according to local policies and individual risk assessment. It should therefore not be regarded as a universal physiological eligibility criterion in the same way as PaO₂.

⸻

Practical Use

12. Home Oxygen

LTOT is usually delivered at home using an oxygen concentrator, with the prescribed flow rate determined during specialist assessment.

Patients and household members require education about safe oxygen use, particularly avoidance of smoking, flames, and other ignition sources.

⸻

13. LTOT Is Different from Oxygen for Breathlessness

LTOT should not be prescribed simply because a patient feels breathless.

A patient can have severe breathlessness while maintaining adequate oxygenation, and supplemental oxygen has not demonstrated the same survival benefit in patients who do not have qualifying chronic hypoxaemia.

The key indication is therefore documented persistent hypoxaemia, not breathlessness alone.

⸻

Key Clinical Pattern

Think of LTOT in a clinically stable patient with persistent severe chronic hypoxaemia despite optimal treatment.

The classic threshold is PaO₂ ≤7.3 kPa (55 mmHg), or approximately 7.3–8.0 kPa (55–60 mmHg) when complications of chronic hypoxaemia such as cor pulmonale/pulmonary hypertension or secondary polycythaemia are present.

Oxygen is generally required for at least 15 hours per day, and the prescription should be titrated to improve oxygenation safely.

Remember that the older requirements of FEV₁ <1.5 L and universal exclusion of smokers are not modern physiological criteria for LTOT, while chronic hypercapnia does not automatically exclude treatment.